Movements in market activity and shifts in investor confidence can often hint at where attention is heading next. Recently, several healthcare-related stocks have experienced a noticeable uptick in trading volume, reflecting heightened interest among market participants. This pattern points to a gradual shift in focus toward companies that may have previously gone largely unnoticed.
Cardiol Therapeutics Inc. (CRDL)
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is strengthening its long-term investment profile through a combination of financial discipline, intellectual property protection, and a clearly defined commercialization pathway. As the company advances toward key clinical milestones, these elements are critical in supporting execution and reducing overall development risk.
Market Momentum
As of April 22, 2026, CRDL closed at $1.51, plunging 7.36%, with trading volume (1.16M shares) significantly above its average of 654,693 shares—indicating heightened activity amid the pullback. With a market cap of $168.637M, the stock remains within its 52-week range ($0.8800–$1.71). A 1-year target estimate of $7.45 continues to suggest meaningful upside potential as clinical and strategic catalysts unfold.
Financial & IP Strength
Cardiol has secured funding into 2027, providing sufficient runway to complete its Phase III MAVERIC trial and advance pipeline assets such as CRD-38. In addition, the company’s patent portfolio extends through 2040, reinforcing its competitive positioning and supporting long-term revenue potential if its therapies reach commercialization.
Commercial Strategy
Management has outlined plans to pursue partnerships with larger pharmaceutical companies to support global commercialization. This strategy could accelerate time to market, reduce operational risk, and provide access to established expertise in regulatory, manufacturing, and distribution.
Outlook
With strong financial backing, long-term intellectual property protection, and a partnership-driven approach, Cardiol is well-positioned to transition toward commercialization, contingent on successful clinical outcomes.
Apyx Medical Corp (APYX)
Apyx Medical Corp (NASDAQ: APYX) started the day on April 22, 2026, with a price decrease of -1.79% at $3.83. During the day, the stock rose to $4.11 and sank to $3.82. Taking a more long-term approach, APYX posted a 52-week range of $0.83-$4.50.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 4.74%. Meanwhile, its Annual Earnings per share during the time was 4.74%. Nevertheless, the stock’s Earnings Per Share (EPS) this year is -19.26%. This publicly-traded company’s shares outstanding now amount to $41.79 million, simultaneously with a float of $36.28 million. The organization now has a market capitalization of $160.21 million.
Oramed Pharmaceuticals Inc (ORMP)
As of April 22, 2026, Oramed Pharmaceuticals Inc (NASDAQ: ORMP) got off with the flyer as it spiked 1.30% to $3.9. During the day, the stock rose to $3.94 and sank to $3.86. Taking a long-term approach, ORMP posted a 52-week range of $1.84-$3.96.
This publicly-traded company’s shares outstanding now amount to $39.28 million, simultaneously with a float of $31.16 million. The organization now has a market capitalization of $157.74 million. Its Quick Ratio in the last reported quarter now stands at 6.98. Alongside those numbers, its P/E ratio stands at $2.63, and its Beta score is 1.28.